Vepdegestrant Outperforms Fulvestrant in Mutant ER+ Breast Cancer
In a groundbreaking development in the treatment of hormone receptor-positive breast cancer, recent findings have revealed that the novel PROTAC-based selective estrogen receptor degrader (SERD)...
















